Changes in Macrophage Function After Rituximab Treatment in Patients with Rheumatoid Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Dec 7

PMID 17148544

Citations 31

Authors

E Toubi

A Kessel

G Slobodin

N Boulman

E Pavlotzky

D Zisman

M Rozenbaum

I Rosner

Affiliations

Soon will be listed here.

Abstract

Objective: To assess changes in macrophage phenotype and function after rituximab-induced B cell depletion in patients with rheumatoid arthritis (RA).

Methods: 10 patients with RA were treated with rituximab, achieving significant B cell depletion 4 months later. Clinical improvement, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, mRNA of B cell activating factor (BAFF), interleukin (IL) 10 and CD86 in human monocyte-derived macrophages (HMDMs) and tumour necrosis factor alpha (TNFalpha) secretion from cultured HMDMs were assessed at baseline and after the depletion.

Results: A clinical response of American College of Rheumatology (ACR) 50% improvement was noted in six patients, and another two patients responded with moderate improvement, equivalent to ACR 20-50% improvements. RF and anti-CCP antibodies were positive at baseline in seven of ten patients. RF disappeared or declined in six patients 4 months after treatment, correlating with clinical improvement. By contrast, anti-CCP remained unchanged in six patients. After rituximab treatment, and in association with clinical improvement, BAFF, IL10 and CD86 mRNA expression in HMDM were significantly upregulated compared with values at baseline. A significant decrease in TNFalpha in the supernatant of cultured HMDM was also noted.

Conclusions: In addition to B cell depletion and attenuation in some of the specific autoantibodies, clinical improvement in rituximab-treated patients with RA occurred in association with changes in macrophage function.

Citing Articles

Disease Activity and Tendency to Relapse in ANCA-Associated Vasculitis Are Reflected in Neutrophil and Intermediate Monocyte Frequencies.

Smargianaki S, Elmer E, Lilliebladh S, Ohlsson S, Pettersson A, Hellmark T J Immunol Res. 2024; 2024:6648265.

PMID: 38213873 PMC: 10781522. DOI: 10.1155/2024/6648265.

Aberrant Activation of Immune and Non-Immune Cells Contributes to Joint Inflammation and Bone Degradation in Rheumatoid Arthritis.

Nandakumar K, Fang Q, Wingbro Agren I, Bejmo Z Int J Mol Sci. 2023; 24(21).

PMID: 37958864 PMC: 10648236. DOI: 10.3390/ijms242115883.

Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients.

Avdeeva A, Cherkasova M, Nasonov E Dokl Biochem Biophys. 2023; 511(1):187-194.

PMID: 37833605 PMC: 10739558. DOI: 10.1134/S160767292370031X.

Off-Label Uses of Rituximab in Dermatology.

Cole C, Amber K Curr Dermatol Rep. 2022; 11(4):209-220.

PMID: 36217351 PMC: 9534735. DOI: 10.1007/s13671-022-00375-4.

Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and Cancer.

Degboe Y, Poupot R, Poupot M Int J Mol Sci. 2022; 23(3).

PMID: 35163420 PMC: 8835955. DOI: 10.3390/ijms23031496.

References

Lipsky P . Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001; 2(9):764-6. DOI: 10.1038/ni0901-764. View

Cambridge G, Leandro M, Edwards J, Ehrenstein M, Salden M, Bodman-Smith M . Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003; 48(8):2146-54. DOI: 10.1002/art.11181. View

Thien M, Phan T, Gardam S, Amesbury M, Basten A, Mackay F . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20(6):785-98. DOI: 10.1016/j.immuni.2004.05.010. View

Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81. DOI: 10.1056/NEJMoa032534. View

Shlomchik M, Madaio M, Ni D, Trounstein M, Huszar D . The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med. 1994; 180(4):1295-306. PMC: 2191708. DOI: 10.1084/jem.180.4.1295. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F . Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood. 2004; 105(2):830-7. DOI: 10.1182/blood-2004-02-0564. View

Ogden C, Pound J, Batth B, Owens S, Johannessen I, Wood K . Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol. 2005; 174(5):3015-23. DOI: 10.4049/jimmunol.174.5.3015. View

Pincus T, Amara I, Koch G . Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005; 52(4):1031-6. DOI: 10.1002/art.20995. View

10.

Sfikakis P, Boletis J, Tsokos G . Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005; 17(5):550-7. DOI: 10.1097/01.bor.0000172798.26249.fc. View

11.

Park H, Park O, Shin J . Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells. Exp Mol Med. 2006; 37(6):524-32. DOI: 10.1038/emm.2005.65. View

12.

Crawford A, MacLeod M, Schumacher T, Corlett L, Gray D . Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol. 2006; 176(6):3498-506. DOI: 10.4049/jimmunol.176.6.3498. View

13.

Cambridge G, Stohl W, Leandro M, Migone T, Hilbert D, Edwards J . Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006; 54(3):723-32. DOI: 10.1002/art.21650. View

14.

Brennan F, Foey A, Feldmann M . The importance of T cell interactions with macrophages in rheumatoid cytokine production. Curr Top Microbiol Immunol. 2006; 305:177-94. DOI: 10.1007/3-540-29714-6_9. View

15.

Reinhardt R, Hong S, Kang S, Wang Z, Locksley R . Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J Immunol. 2006; 177(3):1618-27. DOI: 10.4049/jimmunol.177.3.1618. View